Disclaimer: You are now leaving www.beiresources.org and are going to a website that is not operated by BEI Resources. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE: BEI Resources offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the BEI Resources website and will be redirected to another site. These sites are not under the control of BEI Resources. BEI Resources is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than BEI Resources policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
Yes, BEI Resources does accept hybridoma desposits. BEI Resources does not distribute the hybridoma cell stocks but rather the culture supernatants or purified monoclonal antibodies to registrants.
Beckford-Vera, D.R., et al., First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nature Communications, 2022. 13(1): p. 1219.
Cooper, L., J.G. Achi, and L. Rong, Comparative analyses of small molecule and antibody inhibition on glycoprotein‐mediated entry of Měngla virus with other filoviruses. Journal of Medical Virology, 2022.
DeCotes, D., et al., Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity. Archives of Virology, 2022: p. 1-9.
Evans, J.P., et al., Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Science translational medicine, 2022. 14(637): p. eabn8057.
Heydarchi, B., et al., Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Reports Medicine, 2022. 3(5): p. 100635.